Ligustilide forms an irreversible bond with the Cys129 site of HMGCS1 through its metabolic intermediate, leading to a significant reduction in HMGCS1 enzyme activity and thus effectively ameliorating dyslipidemia induced by a high-fat diet in mice (Zhang et al., 2023). Here, HMGCS1 is linked to metabolic syndrome.